BioDrugs

, Volume 26, Issue 6, pp 425–430

A/H5N1 Prepandemic Influenza Vaccine (Vepacel®): A Guide to Its Use

  • Gillian M. Keating
  • Greg L. Plosker
  • Katherine A. Lyseng-Williamson
Adis Drug Clinical Q&A

DOI: 10.1007/BF03261899

Cite this article as:
Keating, G.M., Plosker, G.L. & Lyseng-Williamson, K.A. BioDrugs (2012) 26: 425. doi:10.1007/BF03261899

Abstract

Vepacel® is a prepandemic influenza vaccine (whole virion, Vero cell-derived, inactivated) containing antigen of H5N1 strain A/Vietnam/1203/2004 and is approved for use in the EU. Clinical immunogenicity studies with the vaccine have demonstrated good functional neutralizing antibody responses against the vaccine strain (A/Vietnam/1203/2004), and cross-reactivity against H5N1 strains from other clades. In general, adverse events observed in clinical immunogenicity studies with a whole virions H5N1 vaccine (A/Vietnam/1203/2004) were similar to those reported with non-adjuvanted, inactivated, split virion seasonal influenza vaccines.

Copyright information

© Springer International Publishing AG 2012

Authors and Affiliations

  • Gillian M. Keating
    • 1
  • Greg L. Plosker
    • 1
  • Katherine A. Lyseng-Williamson
    • 1
  1. 1.AdisAucklandNew Zealand